title: Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model.
abstract: Pseudomonas aeruginosa is one of the most important pathogens in patients with chronic airway conditions, such as cystic fibrosis and diffuse panbronchiolitis. Type III secretion system-mediated virulence factors contribute to the lung damage in chronic P. aeruginosa infection. The effects of the anti-PcrV immunoglobulin (Ig)G, which blocks the type III secretion system, were evaluated in a mouse model of chronic P. aeruginosa infection. On bacteriological examination, anti-PcrV IgG showed no bactericidal effects. On bronchoalveolar lavage fluid (BALF) analysis, total cell number and neutrophil ratios in the anti-PcrV IgG-treated groups were lower than those in the control group. In addition, macrophage inflammatory protein-2, tumour necrosis factor-alpha, and interleukin-beta concentrations in BALF were lower in the anti-PcrV IgG-treated groups when compared with controls. Plasma anti-PcrV IgG titre was elevated after administration of anti-PcrV IgG. Although plasma titre decreased gradually, a significant concentration was maintained during the experimental period. These data suggest that anti-PcrV immunoglobulin G reduces the inflammatory reaction caused by chronic Pseudomonas aeruginosa respiratory infection and may be useful in treating respiratory diseases.
authors.affiliation: Second Dept of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Imamura
authors.forename: K
authors.initials: K
authors.lastname: Yanagihara
authors.forename: Y
authors.initials: Y
authors.lastname: Fukuda
authors.forename: Y
authors.initials: Y
authors.lastname: Kaneko
authors.forename: M
authors.initials: M
authors.lastname: Seki
authors.forename: K
authors.initials: K
authors.lastname: Izumikawa
authors.forename: Y
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Y
authors.initials: Y
authors.lastname: Hirakata
authors.forename: T
authors.initials: T
authors.lastname: Sawa
authors.forename: J P
authors.initials: JP
authors.lastname: Wiener-Kronish
authors.forename: S
authors.initials: S
authors.lastname: Kohno
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000378:metabolism / Q000627:therapeutic use*; D000942:Antigens, Bacterial / Q000276:immunology*; D001427:Bacterial Toxins / Q000276:immunology*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D007140:Immunoglobulin Fab Fragments / Q000378:metabolism / Q000627:therapeutic use*; D007074:Immunoglobulin G / Q000378:metabolism / Q000627:therapeutic use; D008297:Male; D051379:Mice; D052899:Pore Forming Cytotoxic Proteins; D011552:Pseudomonas Infections / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology / Q000472:pathogenicity*; D012141:Respiratory Tract Infections / Q000276:immunology / Q000382:microbiology / Q000628:therapy*
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D052899:Pore Forming Cytotoxic Proteins; C118546:antigen V, Pseudomonas